LOXO-435 Shows Promise as Selective FGFR3 Inhibitor in Metastatic Urothelial Cancer Trial
Key Insights
Phase 1 FORAGER-1 trial demonstrates LOXO-435's superior safety profile with 41% objective response rate in metastatic urothelial cancer (search) patients with FGFR3 (search) alterations.
The drug showed remarkable efficacy in erdafitinib-resistant patients, achieving a 50% response rate in those previously treated with FGFR inhibitors.
Unlike current FGFR inhibitors, LOXO-435's high selectivity for FGFR3 (search) resulted in fewer side effects, particularly reducing skin and ocular toxicities common with erdafitinib.
The landscape of metastatic urothelial cancer (search) treatment may be shifting with promising results from the first-in-human phase 1 FORAGER-1 trial of LY3866288 (LOXO-435), presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.
Advancing Targeted Therapy in Urothelial Cancer
FGFR3 (search) genetic alterations, present in up to 20% of metastatic urothelial cancer (search) cases, have emerged as a crucial therapeutic target. While erdafitinib, the current FDA-approved treatment, targets multiple FGFR isoforms (1, 2, 3, and 4), LOXO-435 represents a new generation of highly selective FGFR3 inhibitors designed to minimize off-target effects.
Impressive Safety Profile
The dose escalation study, ranging from 6 mg daily to 400 mg twice daily, demonstrated remarkable tolerability with no dose-limiting toxicities. Dr. Gopa Iyer, genitourinary medical oncologist and section head of bladder cancer at Memorial Sloan Kettering Cancer Center, highlighted that the most common side effect was low-grade, manageable diarrhea.
"What was most important was that many of the side effects that we see that are the high-grade toxicities with erdafitinib, specifically skin toxicities and ocular toxicities, were notably quite low or even absent with LOXO-435," noted Dr. Iyer.
Compelling Efficacy Data
The trial's efficacy results are particularly encouraging:
- 41% objective response rate among 39 patients with metastatic urothelial cancer
- 50% response rate (6 out of 12 patients) in those previously treated with FGFR inhibitors
- Comparable efficacy to erdafitinib with a superior safety profile
Future Directions
The research team is currently optimizing dosing regimens and planning expansion cohorts. A particularly noteworthy development is the planned investigation of a triplet therapy combining LOXO-435 with enfortumab vedotin and pembrolizumab, the current first-line combination treatment for metastatic urothelial cancer (search).
This innovative approach could potentially reshape the treatment paradigm for patients with FGFR3 (search)-altered metastatic urothelial cancer (search), offering a more targeted and better-tolerated therapeutic option.